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Abstract
Background: Severe pneumonia (SP) is a major complication of respiratory system diseases that is associated with
high mortality and morbidity. If not treated correctly, it may rapidly lead to sepsis and multiple organ dysfunction
syndrome. Despite continuous developments in antibiotic treatments for SP, the mortality rate remains high. Both
basic and clinical research show that Xuebijing injection (XBJ) can improve the symptoms of SP. The aim of this
study is to evaluate the effectiveness and safety of XBJ compared with placebo.
Methods/design: This multicenter, blinded, randomized controlled trial will be conducted with a total of 700
participants with SP. Using a central randomization system, participants will be randomized (1:1) into groups
receiving either XBJ or placebo (within 24 h of diagnosis of SP) for 5–7 days with a 28-day follow-up. All
participants will receive conventional treatment simultaneously. Both XBJ and placebo will be administered using a
photophobic infusion set to avoid bias. The primary outcome is improvement of Pneumonia Severity Index risk rate.
Adverse events will be monitored throughout the trial.
Discussion: This is the first and largest randomized trial done in China on SP treatment using a Chinese herbal
extract. In this trial, we will use central randomization and an electronic case report form, and we have designed an
innovative blinding method for the traditional Chinese medicine injection. The results of this trial may help to
provide evidence-based recommendations to clinicians for treatment of SP.
Trial registration: Chinese Clinical Trials Registry ChiCTR-TRC-13003534. Registered 24 June 2013.
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Background
Severe pneumonia (SP) is one of the leading causes
of death in patients in the intensive care unit (ICU)
[1]. The average mortality in hospitalized patients
with SP is between 15 % and 30 %, with a mortality
rate of between 50 % and 60 % in the ICU [2, 3];
thus, patients with SP represent a major concern for
physicians [4, 5]. If not treated properly, SP may
eventually lead to complications that include multiple
organ dysfunction syndrome (MODS) and sepsis,
which is characterized by persistent inflammation [6],
and ultimately death.
Clinical and basic research have revealed that SP is
associated with bacterial or viral infections. In re-
sponse to invasion by pathogenic microorganisms,
sustained release of inflammatory mediators leads to
systemic inflammatory response syndrome (SIRS) and
coagulopathy [7, 8]. Therefore, in addition to active
and early treatment for pathogenic microorganisms
using antibiotics, anti-inflammatory and anticoagulant
therapy may improve the prognosis of patients
with SP. Currently, the main therapeutic strategy
for SP involves administration of antibiotics and
anti-inflammatory agents [9]. However, long-term
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antibiotic therapy not only increases the risk of anti-
biotic resistance but also produces liver and kidney
toxicity and other side effects [10]. Moreover, previ-
ous anti-inflammatory strategies showed limited effi-
cacy in clinical trials, in part because they targeted
single cytokines [11]. Compared with Western medi-
cine, traditional Chinese medicine (TCM) has been
shown in recent studies to have promising results for
the treatment of SP [12, 13], indicating that, used in
complementary and alternative therapies, TCM may
represent a novel therapeutic approach for SP.
Wang Jinda, a founder of emergency medicine in
China, proposed that integrative medicine therapy can
raise the cure rate in acute critical disease [14]. He sum-
marized four rules for four syndromes of intensive and
critical care based on prescriptions of a toxin-resolving,
blood-quickening decoction (解毒活血汤) and house of
blood-expelling decoction (血府逐瘀汤) described by
Wang Qingren, a famous physician of the Qing dynasty
[8]. Through pharmacodynamic screening, he developed
the Xuebijing (XBJ) injection [15], a formula composed
of five medicinal herbs. Safflower (hong hua) acts as the
sovereign drug, activating blood circulation and remov-
ing blood stasis, while red peony root (chi shao) and
Ligusticum wallichii (chuang xiong) function as the min-
ister drug, cooling blood, dispersing blood stasis, and de-
toxifying and magnifying the effects of the sovereign
drug to activate blood and move qi. Salvia miltiorrhiza
(dan shen) and Angelica sinensis (dang gui) are assistants
which enrich blood and disperse stasis.
In the TCM perspective, the basic pathogenesis of SP
is blood stasis and toxicity blockade. XBJ, a Chinese pa-
tent medicine for the symptomatic treatment of SP, has
the effect of promoting blood circulation and removing
blood stasis, as well as mediating fever attenuation and
detoxification. The main components of XBJ are hydro-
xysafflor yellow A, paeoniflorin, ferulic acid, and salvia-
nolic acid B. Basic research has confirmed that XBJ
functions as an endotoxin antagonist, an anti-
inflammatory agent, and an anticoagulant and that it
regulates immune function [16–19]. Previous clinical
studies showed that routine medication combined with
XBJ may reduce infection indicators and the levels of in-
flammatory cytokines induced by SP [20]. The present
clinical study is associated with limitations of sample
size, clinical treatment time, and nonuniform drug dos-
age, as well as with inconsistencies in inclusion and ex-
clusion criteria. Therefore, a large-scale, multicenter,
blinded, randomized clinical trial (RCT) is required to
confirm the efficacy and safety of XBJ injection for the
treatment of SP.
The aim of this trial is to evaluate the effectiveness
and safety of XBJ injection for SP in China by compari-
son with a placebo.
Methods/design
Research type
We are conducting a randomized, controlled, blinded,
multicenter trial.
Study setting
The hospitals enrolled in this study are all tertiary refer-
ral medical centers, including 28 Western medicine hos-
pitals and 2 TCM hospitals. All of these hospitals are
listed in Table 1.
Study criteria
The patients enrolled in this study should meet the diag-
nostic and inclusion criteria and provide written in-
formed consent.
Diagnostic criteria
The diagnostic criteria we will use for SP are based on
the Infectious Diseases Society of America/American
Thoracic Society guidelines [21]. The criteria for SIRS
are based on the 1991 Chicago meeting standards [22].
Inclusion criteria
The inclusion criteria are as follows:
1. Age ≥18 years and ≤75 years, male or female
2. Weight ≥40 kg and ≤100 kg
3. Meet the diagnostic criteria for SP
4. Meet the diagnostic criteria for SIRS
5. Provide signed informed consent
Exclusion criteria
The exclusion criteria are as follows:
1. Diagnosis of SP for more than 48 h
2. Pregnant and lactating women
3. Disorders likely to have serious effects on survival of
the primary disease (such as unresectable tumors,
blood diseases, prolonged bed rest caused by
cerebrovascular diseases, Alzheimer’s disease, or HIV)
4. Using immunosuppressants, hormones (a
cumulative total methylprednisolone dose
≥1500 mg), and/or using cytotoxic drugs within the
previous 6 months, or using all of these drug types
within the previous 7 days
5. Pneumonitis, interstitial pulmonary fibrosis, alveolar
proteinosis, and allergic alveolitis induced by
obstructive lung tumors
6. Psychiatric patients
7. Allergies (to two or more substance allergies)
8. Participation in other clinical trials in the previous
30 days
9. Using prohibited drugs in the 7 days before
enrollment
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Table 1 Research settings and name of each ethics committee
Research setting Ethics committee name Approval registration
number
Zhongshan Hospital, Fudan University Medical ethics committee of Zhongshan Hospital, Fudan University 2011-(38)3
Second Military Medical University, Changhai
Hospital
Medical ethics committee of Second Military Medical University,
Changhai Hospital
CHEC2013-107
First Teaching Hospital of Tianjin University of
Traditional Chinese Medicine
Medical ethics committee of First Teaching Hospital of Tianjin
University of Traditional Chinese Medicine
SLK2012012-1
Tianjin Medical University General Hospital Drug ethics committee of Tianjin Medical University General Hospital IRB2013-021-02
People’s Liberation Army General Hospital of
Shenyang Military Region
Medical ethics committee of People’s Liberation Army General
Hospital of Shenyang Military Region
k2013-02
First Affiliated Hospital of Dalian Medical University Ethics committee of First Affiliated Hospital of Dalian Medical
University
LCSY2014-02
Second Affiliated Hospital of Harbin Medical
University
Medical ethics committee of Second Affiliated Hospital of Harbin
Medical University
2013-研-012
Chinese People’s Liberation Army General Hospital Medical ethics committee of Chinese People’s Liberation Army
General Hospital
C2014-001-01
First Affiliated Hospital of Chinese People’s
Liberation Army General Hospital
Medical ethics committee of First Affiliated Hospital of Chinese
People’s Liberation Army General Hospital
C2014-001-01
Qilu Hospital of Shandong University National drug clinical trial ethics committee of Qilu Hospital of
Shandong University
2013068(1)
Second Affiliated Hospital of Hebei Medical
University
Medical ethics committee of Second Affiliated Hospital of Hebei
Medical University
2013EC10-01-1
Beijing Union Medical College Hospital, Chinese
Academy of Medical Sciences
Ethical review committee of Beijing Union Medical College Hospital,
Chinese Academy of Medical Sciences
S-519
People’s Liberation Army Air Force General
Hospital
Ethics committee of People’s Liberation Army Air Force General
Hospital
空总药字第2013-04
People’s Liberation Army Second Artillery General
Hospital
Ethics committee of People’s Liberation Army Second Artillery
General Hospital
2013013
People’s Hospital of Wuhan University Medical ethics committee of People’s Hospital of Wuhan University [2013]伦审字(066)号
Zhongnan Hospital of Wuhan University Medical ethics committee of Zhongnan Hospital of Wuhan University (2013)伦审字(024)号
Wuhan General Hospital of Guangzhou Military
Region, People’s Liberation Army
Medical ethics committee of Wuhan General Hospital of Guangzhou
Military Region, People’s Liberation Army
[2013]005-2号
The First Hospital of Jilin University Ethics committee of The First Hospital of Jilin University (2014)临审第(140512-
049)号
Xin Hua Hospital affiliated with Shanghai Jiaotong
University School of Medicine
Medical ethics committee of Xin Hua Hospital affiliated with
Shanghai Jiaotong University School of Medicine
XHEC-A-2013-041-2
People’s Liberation Army Guangzhou Military
General Hospital
Institutional review board for clinical trials of People’s Liberation
Army Guangzhou Military General Hospital
批件(2014)-0014




Hunan Provincial People’s Hospital Medical ethics committee of Hunan Provincial People’s Hospital [2015]-06
Beijing Millennium Monument Hospital Medical ethics committee of Beijing Millennium Monument Hospital (2013)伦审第(57)号
People’s Liberation Army Beijing Military General
Hospital
Institutional review board for clinical trials of People’s Liberation
Army Beijing Military General Hospital
BZEC2013-063
Shiyan Taihe Hospital Drug clinical trials ethics committee of Shiyan Taihe Hospital 2015第(01)号
Yuhuangding Hospital Affiliated with Qingdao
University




Guangdong Province Chinese Medicine Hospital Ethics committee of Guangdong Province Chinese Medicine Hospital 广东省中医院伦理委员
会B2013-165-01
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10. Patients diagnosed with severe acute respiratory
distress syndrome [23]
11. Patients who were unsuitable for participation in
this trial or unable to complete the follow-up ac-
cording to the judgment of the investigators
Other criteria
Forbidden and concomitant drugs The following cri-
teria apply to forbidden and concomitant drugs:
1. Use of prohibited medicines, including ulinastatin as
well as TCM injections with efficacy similar to that
of XBJ, such as Tanreqing and Reduning
2. Details of any additional drugs or therapy must be
recorded in the case report form (CRF), including
the drug name, dose, and treatment duration
Suspension criteria The criteria for suspension of par-
ticipation are as follows:
1. Poor compliance of investigators or patients
2. Occurrence of serious adverse events (AEs),
complications, or fatal physiological changes
3. Using forbidden medications or treatments during
the trial that might affect analysis of the results
4. Voluntary withdrawal
5. Incomplete data
6. Withdrawal for various reasons, such as death or
failure to attend follow-up visits
Interventions
Methods of administration
The treatment group receives routine medication [24]
plus XBJ injection (specification 10 ml/piece, pack-
aging 10 pieces/container). The control (placebo)
group receives routine medication plus a 0.9 % so-
dium chloride injection. The dosage and speed of in-
jection for the placebo are identical to the XBJ
injection (100 ml twice daily, intravenous drip for
more than 80 minutes).
Routine medications for SP
The routine medications used in this trial for SP are as
follows:
1. Types of antibiotics: A β-lactam (cefotaxime, cef-
triaxone, or ampicillin/sulbactam) plus either a
macrolide (azithromycin, clarithromycin, or
erythromycin) or a fluoroquinolone (for
penicillin-allergic patients, a respiratory fluoro-
quinolone and aztreonam); for Pseudomonas
infection, a β-lactam (piperacillin/tazobactam,
cefepime, imipenem, or meropenem) plus either
ciprofloxacin or levofloxacin; or the above
β-lactam plus an aminoglycoside and an
antipneumococcal fluoroquinolone (for penicillin-
allergic patients, substitute aztreonam for the
above β-lactam)
2. Dosage of hormones: Using hormones is one
of our exclusion criteria; however, during the
intervention period (5–7 days), low-dose ( 1 mg/
kg/day), methylprednisolone can be given if
necessary
Dispensing and combination methods
The dispensing and combination methods used in this
trial are as follows:
1. XBJ (100 ml) is diluted to 200 ml using saline as a
solvent.
2. The use of other injections simultaneously
during the course of intravenous infusions is
prohibited.
3. Other injections should be separated by injection of
50 ml of saline.
Precautions
The precautions we will observe are as follows:
1. Patients receive the study drug within 24 h of
enrollment.
2. The routine treatment of SP (e.g., antibiotics,
hormones, anticoagulants, vasopressors) should be
carried out simultaneously and XBJ injection should
not be used as a substitute.
Table 1 Research settings and name of each ethics committee (Continued)
First Affiliated Hospital of Fourth Military Medical
University
Drug clinical trials ethics committee of First Affiliated Hospital of
Fourth Military Medical University
KY20140813-3
The First Affiliated Hospital of Anhui Medical
University




The Fourth Affiliated Hospital of China Medical
University
Medical ethics committee of The Fourth Affiliated Hospital of China
Medical University
2015-020
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Sample size
Previous studies [25, 26] showed that the improvement
of PSI risk rating of the control group is 70 %. Assuming
that the improvement in the treatment group is 10 %
higher than that in the control group, the sample size is
calculated according to the parameters α = 0.05 (two-
sided test) and β = 0.2. Using PASS 11 software (NCSS
Statistical Software, Kaysville, UT, USA), we calculated
that 291 patients should be recruited into each group.
Considering an attrition rate of no more than 15 %, the
eligible participants in each group should be no fewer
than 342. Therefore, we determined that we would need
a sample size of 350 in each group (n = 700).
Randomization
The randomization of the trial will be completed at an
independent data center using a central randomization
system to achieve dynamic minimization randomization.
When a subcenter accepts an eligible participant, re-
searchers will log into the central randomization system
to enter stratified factor information of the patient, in-
cluding age, mechanical ventilation condition, and the
source of infection (community- or hospital-acquired in-
fection). The central randomization system will then as-
sign an identification code and a random number




The blinding methods used in this trial are as follows:
1. Investigators and drug administrators have
independent authority to log into the central
randomization system. The investigators are
responsible for screening subjects, obtaining
informed consent, entering patients’ information
into the system, and obtaining a random number;
however, the patients’ group assignment is
concealed. After the subjects are randomly assigned
by the investigators, drug administrators will log
into the system to obtain the patient’s group with
the random number and assign the study drugs to
subjects.
2. Both the XBJ and placebo are administered using
the photophobic infusion set to avoid the subjects’
ascertaining their group assignment.
3. Both the paper and electronic CRFs are filled in with
the patient’s random number only, while details of
the group information are not included.
4. During the course of the study, investigators and drug
administrators work relatively independently, both
having signed a confidentiality agreement that
prohibits any disclosure of group-related information.
5. Unblinding is divided into two processes by the
interactive web response system (IWRS) central
randomization system. First, after data-locking, the
random numbers corresponding to the group code
(e.g., A group, B group) are revealed. Second, when
the statistical report is fixed, the actual group will be
revealed.
Emergency unblinding
If knowledge of the patient’s group is required in the
event of an emergency or a requirement for rescue, re-
searchers first obtain details of the patient’s group from
the drug administrators, then the reason for the unblind-
ing will be reported to the major investigators within
24 h. The subjects are withdrawn from the study after
unblinding. Detailed unblinding cause, date, treatment
situation, and results will be reported in the CRF and
signed by the administrator.
Content and points of data capture
The content and points of data capture in the trial are as
follows:
1. Screening period (1 day): 24 h before recruitment
2. Intervention period (5–7 days): follow-up every day
and recorded
3. Period after intervention (within 28 days after
treatment): follow-up at day 8 and day 28
Different items are measured according to the time




The primary outcome of this trial is the improvement of
the PSI risk rating [27]. The evaluation criteria are as
follows:
1. Significantly effective: the risk rating decreases two
levels
2. Effective: the risk rating decreases one level
3. Ineffective: no change or deterioration in the risk
rating
Evaluation of improvement in PSI risk rating is the
sum of the total numbers of significantly effective and
effective divided by the total number, multiplied by
100 %.
Secondary outcome measures
The secondary outcome measures are as follows:
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1. SIRS improvement: determined according to changes
in the SIRS diagnostic indicators [28] before and
after the intervention. These evaluation criteria are
as follows:
a. Significantly effective: the symptoms improved
(three or four diagnostic indicators change from
abnormal to normal)
b. Effective: the symptoms were relieved (two
diagnostic indicators change from abnormal to
normal)
c. Ineffective: no change or deterioration in the
symptoms (only one diagnostic indicator changes
from abnormal to normal, or other condition)
d. SIRS improvement degree is measured as the sum
of the total numbers of significantly effective and
effective divided by the total number, multiplied
100 %
2. Lung Injury Score (LIS) improvement: only for
patients with ventilation; the evaluation criteria are
based on those defined by Murray and colleagues
Table 2 Content and points of data capture
Content Screening Intervention After intervention
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 Visit 10
Day 0 1 2 3 4 5 6 7 8 28




Get SSID and random number Χ
History of SP and treatment Χ
History of medication and treatment Χ
Concomitant diseases Χ
Complications Χ Χ Χ Χ Χ Χ Χ Χ Χ
Body weight and body mass index Χ Χ
Vital signs Χ Χ Χ Χ Χ Χ Χ Χ Χ
Laboratory tests Χ Χ Χ
Safety outcomes Χ Χ Χ Χ
Mean arterial pressure Χ Χ Χ Χ Χ Χ Χ Χ Χ
Central venous pressure Χ Χ Χ Χ Χ Χ Χ Χ Χ
Blood gas analysis Χ Χ Χ Χ Χ Χ Χ Χ Χ
Mechanical ventilation parameters Χ Χ Χ Χ Χ Χ Χ Χ Χ
Chest x-ray or CT scan Χ Χ Χ
Sputum and blood culture Χ Χ Χ Χ Χ Χ Χ Χ Χ Χ
Record of routine treatment Χ Χ Χ Χ Χ Χ Χ
Issue study drug Χ Χ Χ Χ Χ Χ Χ
Record issue and recovery drug Χ Χ Χ Χ Χ Χ Χ
Record adverse events Χ Χ Χ Χ Χ Χ Χ
Severity-of-illness scores Χ Χ Χ
Stage efficacy evaluation Χ Χ
Length of mechanical ventilation Χ Χ Χ Χ Χ Χ Χ Χ Χ
Length of stay in ICU Χ Χ Χ Χ Χ Χ Χ Χ Χ
Length of hospitalization Χ Χ Χ Χ Χ Χ Χ Χ Χ
Length of antibiotic use Χ Χ Χ Χ Χ Χ Χ Χ Χ
Efficacy and safety evaluation Χ
Main treatment affecting prognosis Χ
Survival follow-up Χ
CT computed tomography, ICU intensive care unit, SP severe pneumonia
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[29] according to the changes in LIS before and after
the intervention (Table 3), measured as LIS
improvement degree equals the sum of significantly,
moderately, and slightly effective divided by the total
number, multiplied by 100 %
3. The highest body temperature
4. MODS score [30, 31] improvement according to the
differences in MODS scores before and after the
intervention:
a. Significantly effective: MODS score decrease ≥7
b. Moderately effective: MODS score decrease 4–6
c. Slightly effective: MODS score decrease 2–3
d. Ineffective: no change or increase in MODS score
e. MODS score improvement degree is measured as
the sum of significantly, moderately, and slightly
effective divided by the total number, multiplied
by 100 %
5. Acute Physiology and Chronic Health Evaluation II
(APACHE II) [32] score improvement according to
the differences in the APACHE II scores before and
after the intervention using the lowest APACHE II
score within 24 h (≤19, low risk; ≥20, high risk)
6. Sequential Organ Failure Assessment [33] score
improvement assessed according to the number of
organ failures (0–1 organ failure, low risk; ≥2 organ
failures, high risk)
7. The changes in inflammation and coagulation
indicators: C-reactive protein, procalcitonin, and D-
dimer
8. Chest x-ray changes
9. The mutual conversion rates of invasive mechanical
ventilation and noninvasive mechanical ventilation
10. Mortality rate after 28 days
11. The time of mechanical ventilation, total duration
of ICU stay, hospitalization, and antibiotic use
12. The time of bacterial cultures becoming negative
Safety outcomes
Safety outcomes, including vital signs, routine blood and
urine tests, fecal occult blood test, hepatic (alanine
transaminase, aspartate transaminase, serum total biliru-
bin) and renal (blood urea nitrogen, creatinine) function,
coagulation index (fibrinogen, prothrombin time, acti-
vated partial thromboplastin time), electrocardiogram
results, and AEs. All of these indicators will be moni-
tored closely throughout the trial.
Adverse events
Every AE occurring during the study must be recorded
in the AE form according to the actual circumstances.
The following information should be recorded: occur-
rence time, severity, duration, adopted measure, and the
outcome of the AE. The number and rate of AEs and
serious AEs of the two groups are recorded. A crossover
table is used to describe the changes in laboratory and
electrocardiogram indicators.
Statistical analysis
The statistical analysis will be performed using SAS soft-
ware version 9.4 (SAS Institute, Cary, NC, USA). Rates
of PSI improvement between the groups will be analyzed
by performing superiority tests. If the lower limit of the
95 % confidence interval is larger than a clinically mean-
ingful difference, therapeutic effects of the experimental
group are deemed to be clinically and statistically better
than those of the control group. Two-sided tests will be
performed for all the other statistical analyses. Cochran-
Mantel-Haenszel χ2 tests or Fisher’s exact tests will be
used for comparison of categorical outcomes. Continu-
ous outcomes will be analyzed by using Student’s t test.




Two data input media will be applied in this study. Re-
searchers add patient information to the paper CRF
promptly and synchronously with input into the elec-
tronic CRF. The occurrence of unexpected problems
during this process should be recorded, and the data
management center will be informed in a timely
manner.
Data verification
In this trial, Oracle Clinical (OC) software (Oracle Corp.,
Redwood Shores, CA, USA) will be used for centralized
data management [34]. Modifications made by clinical
investigators will be checked promptly, and the results
will be reported to the researchers and clinical research
Table 3 Evaluation criteria of Lung Injury Score improvement
Total score of four
items
Total scores for the three items (except lung compliance)
Decrease ≥4 Decrease 2–3 Decrease 1 No change or increase
Decrease ≥6 Significantly effective Significantly effective Significantly effective Significantly effective
Decrease 4–5 Significantly effective Moderately effective Slightly effective Slightly effective
Decrease 2–3 Slightly effective Slightly effective Slightly effective Slightly effective
No change or increase Ineffective Ineffective Ineffective Ineffective
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associates (CRAs). The CRAs are responsible for verify-
ing the consistency and accuracy of the paper and elec-
tronic CRFs and for reporting the results to the clinical
investigators.
Data lockup
Data lockup will be implemented by data management
on completion of the study. Researchers are unable to




Before the trial, caution will be applied in selection of
the participating institutions and investigators. All the
participating institutions will be required to have ap-
proval from the drug clinical trial agency, and all the in-
vestigators will be required to be qualified in the
implementation of Good Clinical Practice (GCP) train-
ing according to the State Food and Drug Administra-
tion (SFDA). Before the trial, investigators will receive
rigorous training and take a comprehensive examination
to improve compliance [35]. In the CRF, the investiga-
tors will be required to provide authentic and reliable
data of combined medication and AE conditions; the
subjects will be required to comply with their medica-
tion regimen and receive follow-up in accordance with
the trial plan; and the drug administrator will ensure ac-
curate recording of the dosage and amount of drug
remaining to monitor patient compliance.
Monitoring and inspection
Both online monitoring and in situ supervision will be
used in this trial. With the support of the “check” func-
tion in the OC software, large-scale clinical trial dynamic
management will be implemented to ensure that the
data are collected completely, promptly, and accurately.
The organizer will nominate monitors for regular visits
to each unit for reexamination of the CRF to ensure
consistency with the original data.
Ethical issues
Ethics statement
Researchers are responsible for ensuring that the study
is conducted in accordance with the principles of the
Declaration of Helsinki and GCP. Participants entirely
voluntarily give their written informed consent before
any study procedures, and they can voluntarily withdraw
from the study for any reason. Parents or guardians are
informed of the risks and benefits of the study if the par-
ticipants have difficulty with decision-making. Each pa-
tient will be identified with a unique random number,
and the private data must be preserved by researchers to
maintain confidentiality.
Ethical approval
The study protocol, informed consent form (ICF), and
other research documents were approved by the medical
ethics committee of Zhongshan Hospital, Fudan Univer-
sity [approval registration number 2011-38(3)]. Other
participating agencies were approved by the medical eth-
ics committee of each hospital. (The names of all ethics
committees that approved our study in every center are
listed in Table 1.)
Clinical trial insurance
Before the trial, “safe clinical trial insurance” was pur-
chased from Ping An Insurance Group (China) (policy
number 10330001900105798721).
Informed consent form
The ICF must be signed by the participants or their rep-
resentatives, and the date must be included. The signed
ICF will be preserved by researchers and participants in-
dependently. The ICF preserved by the researchers will
be made available to project managers for monitoring,
auditing, and inspection.
Discussion
XBJ is a confidential National Technology Product ap-
proved by the Ministry of National Science and Tech-
nology and the State Secrecy Bureau, and is authorized
as a patented product by the State Intellectual Property
Office (patent protection period of 20 years). In 2004,
XBJ was approved for marketing by the SFDA (number
Z20040033). Preliminary clinical trial [36] results indi-
cated that routine medication combined with XBJ can
significantly reduce the death rate due to SP, and can
also decrease the duration of mechanical ventilation and
antibiotic use, with no adverse reactions such as liver
and kidney dysfunction.
Blinding methods
Due to the characteristically colored liquid resulting
from the TCM injection production process [37], it is
difficult to produce a placebo with a similar appearance;
therefore, most previous clinical trials have not been
blinded in design. Such unblinded trials are subject to
risks of selection bias and evaluation bias. To overcome
this issue, we used photophobic infusion sets to imple-
ment a blinded design for the present study. Further-
more, this trial was designed with the aid of computer
technology, using an updated version of the conven-
tional processes of the central IWRS randomization sys-
tem to conceal group information. Investigators and
drug administrators will be given independent authority
to log into this system following signing of a confidenti-
ality agreement. All these methods were used to ensure
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that the blinded design is implemented and maintained
for the duration of the present study.
Strict randomization was implemented to minimize se-
lection bias and evaluation bias. Furthermore, the use of
the photophobic infusion set not only ensured that the
blinded design of this trial was maintained but also
avoided the placebo effect, rendering the research find-
ings fair and objective. To our knowledge, the blinding
and randomization methods used are being adopted in
TCM injection clinical studies for the first time. These
strategies can be used to overcome the difficulties asso-
ciated with the blinded design of such studies, and also
to investigate feasible approaches to clinical evaluation
of other colored agents.
Outcome measures
In this trial, we selected improvement in PSI risk rating
as the primary outcome. PSI risk rating is used to clas-
sify patients with pneumonia into 5 grades of increased
risk for short-term mortality on the basis of 20 variables
that are routinely available at presentation [38]. This risk
rating precisely reflects the condition of patients with
pneumonia [38]. It has been extensively validated in pro-
spective and retrospective studies and is widely used in
hospitals [39–41]. The secondary outcomes of this trial
include several severity-of-illness scoring systems, such
as LIS, MODS, and APACHE II, which reflect the condi-
tion of patients with SP from different perspectives and
are predictive of patient mortality. Most previously re-
ported SP trials used mortality or length of ICU stay as
primary outcomes. However, many types of drugs and
devices are used to treat patients in ICUs; therefore, it is
difficult to establish a significant impact of a novel ther-
apy on mortality among ICU patients. Consequently, in
this study, selected indicators were used to reflect the
condition of patients and to determine the significance
of the therapy.
Safety of XBJ injection
The TCM injection is a new formulation of Chinese
herbs based on a modification of the oral delivery of the
traditional decoction. This alternative is characterized by
rapid and efficient delivery and provides more choice for
the clinical treatment of disease. However, there is little
experience with TCM injections in the clinic; conse-
quently, the safety of this formulation remains to be
confirmed, and incorrect administration may be associ-
ated with AEs. Therefore, TCM injections must be used
cautiously. Confirmation of the safety of XBJ injection as
a TCM is of paramount importance. A meta-analysis of
the efficacy and safety of XBJ injection [42] revealed that
no AEs occurred in 1022 patients who received this
treatment, indicating that XBJ injection is safe. There
are also some reports of the AEs associated with XBJ
injection [43], the majority of which occurred in patients
receiving XBJ for the first time. Of the instances of AEs,
58.8 % occurred within 30 minutes of the injection,
64.7 % were caused by improper use of XBJ, and 47.1 %
were recorded among patients with a history of allergies;
all the patients improved after drug withdrawal.
In this trial, we also selected inflammation and coagu-
lation index as well as hepatic and renal function as
safety outcomes. All of these indicators will be closely
monitored throughout the trial to determine the long-
term safety of XBJ.
Strengths and limitations
This is a first large-sample, multicenter, blind RCT of
TCM injection and was designed on the basis of previ-
ous studies. We adopted the central randomization sys-
tem, electronic CRF, and other advanced systems and
achieved innovative breakthroughs in the blinded design.
The high standards for selection of the participating in-
stitutions and researchers, rigorous training of re-
searchers, and the implementation process for
inspection and other quality control methods were de-
signed to ensure the quality of this trial. Ethical ap-
proval, signed informed consent, and clinical trial
insurance coverage fully protect the interests of the sub-
jects. We selected several severity-of-illness scoring sys-
tems as primary and secondary outcomes for objective
evaluation the effects of XBJ. Throughout the trial, safety
outcomes will be closely monitored to avoid AEs and
crossover tables will be used to describe the changes in
laboratory and electrocardiogram indicators. However,
due to the large sample, the time of participant recruit-
ment is long. The season and climate change may influ-
ence the prognosis of disease. The results of the trial
remain to be confirmed in clinical research practice.
Trial status
Currently, participant recruitment is ongoing.
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